Simple Summary This review analyzes the occurrence, clinical characteristics, and
prognostic impact and treatment of autoimmune hemolytic anemia (AIHA) in chronic …

Autoimmune diseases (AIDs) arise from a breakdown in immunological self-tolerance,
wherein the adaptive immune system mistakenly attacks healthy cells, tissues and organs …

The Rh blood group system has been extensively studied and remains clinically relevant to
transfusion medicine. The system has over 50 antigens; the 5 most significant antigens are …

Warm antibody autoimmune hemolytic anemia (wAIHA) is characterized by hemolysis and
symptomatic anemia with no approved treatment options. Fostamatinib is an oral spleen …

Sutimlimab (sutimlimab-jome; ENJAYMO™) is a humanized monoclonal antibody
developed by Sanofi for the treatment of cold agglutinin disease (CAD). Sutimlimab is an …

Simple Summary Data on immune checkpoint inhibitor (ICI)-related cytopenias are scarce.
The aim of the study was to further characterize grade≥ 2 ICI-related cytopenias using the …

Anaemia is a common health problem worldwide that disproportionately affects vulnerable
groups, such as children and expectant mothers. It has a variety of underlying causes, some …

COVID-19 disease, caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2),
induces a broad spectrum of clinical symptoms ranging from asymptomatic cases to fatal …

Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially life-
threatening pharmacogenic hematological adverse effect. Updating the risk of DIIHA among …

Immune checkpoint inhibitors (ICPis) have revolutionized cancer immunotherapy but also
can induce autoimmune hemolytic anemia (AIHA), a severe disease with high mortality …